Clarkson A R, MacDonald M K, Cash J D, Robson J S
Br Med J. 1972 Jul 29;3(5821):255-60. doi: 10.1136/bmj.3.5821.255.
Treatment with indomethacin, aspirin, or prednisone has been shown to reduce urinary fibrin/fibrinogen degradation products (F.D.P.) in approximately two-thirds of patients with proliferative glomerulonephritis. This reduction which is dose-dependent for prednisone but not for indomethacin or aspirin in the range of doses used occurs within two to three days of beginning treatment and is thought to result from decreased intraglomerular fibrin deposition rather than alteration of glomerular permeability to F.D.P. In patients who responded in this manner treatment was associated with reductions in the degree of proteinuria and maintenance or improvement in renal function.
已证明,使用消炎痛、阿司匹林或强的松治疗,可使大约三分之二的增殖性肾小球肾炎患者尿中纤维蛋白/纤维蛋白原降解产物(F.D.P.)减少。这种减少在开始治疗后的两到三天内出现,对于强的松而言是剂量依赖性的,但在所使用的剂量范围内,消炎痛或阿司匹林并非如此,其被认为是由于肾小球内纤维蛋白沉积减少,而非肾小球对F.D.P.的通透性改变所致。以这种方式产生反应的患者,治疗与蛋白尿程度的降低以及肾功能的维持或改善相关。